There are two trials that will test the addition of the IL-6 inhibitor tocilizumab to ipilimumab/nivolumab in patients with advanced melanoma to observe for differences in PFS/OS while monitoring the toxicity and development of adverse events (NCT03999749 and NCT04940299). Here, IL6 is linked to melanoma.